IVAX Diagnostics, Inc. Announces Name Change to ERBA Diagnostics, Inc.

ZIVAX Diagnostics, Inc. (NYSE MKT: IVD), a fully integrated in vitro diagnostics company, announced today that its corporate name has been changed to "ERBA Diagnostics, Inc." The name change was approved by IVAX Diagnostics’ stockholders at the Annual Meeting of Stockholders held earlier today. IVAX Diagnostics' Board of Directors previously approved the name change, and recommended that the IVAX Diagnostics' stockholders approve the name change.

IVAX Diagnostics’ Board of Directors believes that the name change would be in the best interests of IVAX Diagnostics and its stockholders. The new name would reflect the strong relationship that IVAX Diagnostics enjoys with its majority stockholder — ERBA Diagnostics Mannheim GmbH, an emerging multi-national company operating in the core business segment of in vitro diagnostics.

In connection with the name change, the ticker symbol of IVAX Diagnostics' common stock, par value $0.01, on the NYSE MKT (formerly known as the NYSE Amex) will change from "IVD" to "ERB." Trading under the new ticker symbol, "ERB," is planned to begin at market-open on Monday, June 18, 2012.

About IVAX Diagnostics, Inc.

IVAX Diagnostics, Inc. (www.ivaxdiagnostics.com), headquartered in Miami, Florida, is a fully integrated in vitro diagnostics company that develops, manufactures and distributes in the United States and internationally, proprietary diagnostic reagents, test kits and instrumentation, primarily for autoimmune and infectious diseases, through its three subsidiaries: Diamedix Corporation (U.S.), Delta Biologicals S.r.l. (Europe) and ImmunoVision, Inc. (U.S.).

Safe Harbor Statement

Except for the historical matters contained herein, statements in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect the business and prospects of IVAX Diagnostics, Inc., including, without limitation: the significance of IVAX Diagnostics’ name change and its ability to reflect and capitalize on the strong relationship that IVAX Diagnostics enjoys with its majority stockholder — ERBA Diagnostics Mannheim GmbH; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. In addition to the risks and uncertainties set forth above, investors should consider the economic, competitive, governmental, technological and other risks and uncertainties discussed in IVAX Diagnostics’ filings with the Securities and Exchange Commission, including, without limitation, the risks and uncertainties discussed under the heading “Risk Factors” in such filings.